Company: NCEL
Filing Date: 2025-04-04
Form Type: 6-K/A
Source: 0001213900-25-028988
Chunk: 1

Company: NewcelX Ltd.
Filing Date: 2025-04-04
Form: 6-K/A
Chunk 1
---
 shareholder approval. The Offering closed on March 28, 2025.

The Securities Purchase Agreement
contains customary representations and warranties and agreements of the Company and the investor and customary indemnification rights
and obligations of the parties. In addition, the Company agreed to issue the lead investor up to 435,000 preferred shares (or their equivalent)
to compensate the investor for certain price protection issuances and registration obligations.

The initial closing of the
Offering resulted in gross proceeds to the Company of to $2 million. The Company intends to use the net proceeds from the Offering for
working capital and general corporate purposes, including for expenses relating to its merger with Kadimastem Ltd.

The securities are being offered
pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended, or the Securities
Act, and Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities Act or applicable
state securities laws. Accordingly, once issued, the securities may not be offered or sold in the United States except pursuant to an
effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable
state securities laws.

Committed Equity Facility of up to $25 million

On March 31, 2025, the Company
entered into a Common Shares Purchase Agreement, or the Purchase Agreement, with an institutional investor, or the Investor, relating
to a committed equity facility, or the Facility. Pursuant to the Purchase Agreement, the Company has the right from time to time at its
option to sell to the Investor up to $25.0 million of its common shares, or the Common Shares, subject to certain conditions and limitations
set forth in the Purchase Agreement.

<div align='center'>1</div>

Sales of the Common Shares
to the Investor under the Purchase Agreement, and the timing of any sales, will be determined by the Company from time to time in its
sole discretion and will depend on a variety of factors, including, among other things, market conditions, the trading price of the Common
Shares and determinations by the Company regarding the use of proceeds of such Common Shares. The net proceeds from any sales under the
Purchase Agreement will depend on the frequency with, and prices at which the Common Shares are sold to the Investor. The Company expects
to use the proceeds from any sales under the Purchase Agreement for working capital and general corporate purposes.

Upon